Precision Cancer Medicine and Translational Therapeutics
Cancers develop and respond to therapies differently from one patient to the next. A better understanding of the specific processes driving cancer growth and spread in an individual patient allows for tailored therapeutic strategies that are more effective with minimal side effects. Profiling the mutations and abnormalities that drive a tumor, in combination with development of experimental models that assess the specific responses of cancer cells to therapeutics that target those abnormalities, has dramatically improved outcomes in many cancer types.
The investigators in our department who focus on precision cancer medicine and translational therapeutics research are:
- Sikander Ailawadhi, M.D.
- Panagiotis Z. Anastasiadis, Ph.D.: Cell Adhesion and Metastasis Laboratory
- Yan W. Asmann, Ph.D.
- Esteban Braggio, Ph.D.
- Thomas Caulfield, Ph.D.: Drug Discovery, Design and Optimization for Novel Therapeutics Laboratory
- Marta Chesi, Ph.D.
- John A. Copland III, Ph.D.: Cancer Biology and Translational Research Laboratory
- Alan P. Fields, Ph.D.
- Rajappa S. Kenchappa, Ph.D.
- Keith L. Knutson, Ph.D.
- Kabir Mody, M.D.
- Nadine Norton, Ph.D.
- Tushar C. Patel, M.B., Ch.B.: Molecular Hepatology Laboratory
- Alfredo Quinones-Hinojosa, M.D.: Brain Tumor Stem Cell Research Laboratory
- Evette S. Radisky, Ph.D.: Proteases in Cancer Laboratory
- Steven S. Rosenfeld, M.D., Ph.D.
- Winston Tan, M.D.
- E. Aubrey Thompson, Ph.D.: Hormones and Cancer Laboratory
- Nhan L. Tran, Ph.D.
- Han W. Tun, M.D.
- George Vasmatzis, Ph.D.